DETAILS

Drug ID	DDPD00950
Drug Name	Fexofenadine
Molecular Weight	501.6564
Molecular Formula	C32H39NO4
CAS Number	83799-24-0
SMILES	CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
External Links
	DRUGBANK	DB00950
	T3DB	T3D2938
	PubChem Compound	3348
	PDR	1459
	Drugs.com	Drugs.com Drug Page

Property Name	Property Value	Unit	Raw Value	Raw Unit	Reference
Melting Point	142.5	℃	142.5	℃	PhysProp

Property Name	Property Value	Unit	Raw Value	Raw Unit	Annotation	Factor	Reference
AUC	1367.0	ng.h/ml	1367.0	ng.h/ml	Oral multiple dose;		DRUGBANK
Bioavailability	33.0	%	33	%			DRUGBANK
C Max	299.0	ng/ml	299	ng/ml	Oral multiple dose;		DRUGBANK
C Max	286.0	ng/ml	286±143	ng/ml	PO, oral;		The Pharmacological Basis of Therapeutics
T Max	2.0	h	1-3	h			DRUGBANK
T Max	1.3	h	1.3±0.6	h	PO, oral;		The Pharmacological Basis of Therapeutics
Metabolic	5.0	%	5	%	Liver metabolism;		DRUGBANK
Metabolic	3.6	%	3.6	%			DRUGBANK
Metabolic	1.5	%	1.5	%			DRUGBANK
Clearance	50.6	L/h	50.6	L/h	PO, oral;		DRUGBANK
Clearance	4.2	L/h	4.23	L/h	Renal clearance;		DRUGBANK
Clearance	0.56	L/h/kg	9.4±4.2	ml/min/kg	apparent clearance; PO, oral;		The Pharmacological Basis of Therapeutics
Volume of Distribution	5.6	L/kg	~5.4-5.8	L/kg			DRUGBANK
Half-life	13.0	h	~11-15	h	elimination half-life;		DRUGBANK
Half-life	14.0	h	14±6	h	PO, oral;	mild renal function ↑ ;chronic liver disease → ;	The Pharmacological Basis of Therapeutics
Eliminate Route	80.0	%	~80	%	Faeces excretion;		DRUGBANK
Eliminate Route	11.0	%	11	%	Urinary excretion;		DRUGBANK
Eliminate Route	12.0	%	12	%	Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug;		The Pharmacological Basis of Therapeutics
Protein Binding	65.0	%	60-70	%	plasma proteins;		DRUGBANK
Protein Binding	62.0	%	56-68	%	plasma proteins; RD, renal impairment, Renal disease，including uremia;		DRUGBANK
Protein Binding	65.5	%	56-75	%	plasma proteins; hepatopathy，LD;		DRUGBANK
Protein Binding	65.0	%	60-70	%	adults; Male, men; normal,healthy; human, homo sapiens;		The Pharmacological Basis of Therapeutics

Property Name	Property Value	Unit	Raw Value	Raw Unit	Annotation	Frequency	Brand Name	Component	Reference
Max dose for infants	30.0	mg/day	30	mg/day	PO, oral		Allegra Allergy Tablets	fexofenadine hydrochloride	PDR
Max dose for children	180.0	mg/day	180	mg/day	PO, oral	qd	Allegra Allergy Tablets	fexofenadine hydrochloride	PDR
Max dose for children	120.0	mg/day	120	mg/day	PO, oral	bid	Allegra Allergy Tablets	fexofenadine hydrochloride	PDR
Max dose for children	60.0	mg/day	60	mg/day	PO, oral		Allegra Allergy Tablets	fexofenadine hydrochloride	PDR
Max dose for children	30.0	mg/day	30	mg/day	PO, oral		Allegra Allergy Tablets	fexofenadine hydrochloride	PDR
Max dose for adolescents	180.0	mg/day	180	mg/day	Tablet,PO，oral	qd	Allegra Allergy Tablets	fexofenadine hydrochloride	PDR
Max dose for adolescents	120.0	mg/day	120	mg/day	Tablet,PO，oral	bid	Allegra Allergy Tablets	fexofenadine hydrochloride	PDR
Max dose for adults	180.0	mg/day	180	mg/day	Tablet,PO，oral	qd	Allegra Allergy Tablets	fexofenadine hydrochloride	PDR
Max dose for adults	120.0	mg/day	120	mg/day	Tablet,PO，oral	bid	Allegra Allergy Tablets	fexofenadine hydrochloride	PDR
Max dose for geriatric	180.0	mg/day	180	mg/day	Tablet,PO，oral	qd	Allegra Allergy Tablets	fexofenadine hydrochloride	PDR
Max dose for geriatric	120.0	mg/day	120	mg/day	Tablet,PO，oral	bid	Allegra Allergy Tablets	fexofenadine hydrochloride	PDR

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1